EFPIA - NEWSLETTER

Trouble reading this email? View it in your browser


		EFPIA Newsletter 27 February 2020

European pharmaceutical industry response to coronavirus

Responding to COVID-19 outbreak

As the impact of COVID-19 continues to be felt across the world, including recent deaths in Italy and France, the biopharmaceutical industry in Europe remains committed to global efforts to care for those affected, contain the outbreak and develop resources to tackle future outbreaks.

EFPIA members are heavily engaged in the IMI to fast track collaborative research, identifying any suitable assets in their libraries that could be utilised to develop diagnostics and treatments in the fight against COVID-19. In addition, the industry in Europe is providing financial support and in-kind donations to organisations on the ground as well as working closely with European, Chinese, and Global health authorities to combat this global public health emergency. Read more

#WeWontRest until treatments for rare conditions become less rare

30 million Europeans live with a rare disease: that is 1 in 17 people. Through continued research & innovation, #WeWontRest until treatments for rare conditions become less rare.

Videos

Illness never sleeps #WeWontRest
Illness never sleeps. When everyone else is having 40 winks, illness is running round the block. Illness never sleeps,... Read more

#WeWontRest until we make rare disease even rarer
Rare diseases are far more common than you might think, but treatments are rare. Read more

Events

POSTPONED - China/EU Pharmaceutical Industry Forum 2020
16 March 2020 (Wavre, Belgium)

** Event postponed until Autumn 2020 ** Read more

DIA Europe 2020
29 June 2020 (Virtual Conference)

As a direct result of the outbreak of the coronavirus disease (COVID-19), DIA has decided to postpone DIA Europe 2020... Read more

Clinical Trial Regulation Information Day for CEE Countries
31 March 2020 (Warsaw, Poland)

Are Central and Eastern European Union member states ready to implement the new EU Clinical Trial Regulation (536/2014)?... Read more

NEW DATES - EU Health Summit 2020
26 October 2020 (Virtual event)

The EU Health Coalition is delighted to announce the second edition of the EU Health Summit. Read more

What we are reading

Industry groups play down Coronavirus’ immediate risk to medicine supplies
On 25 February 2020 (ThePharmaLetter)

Global efforts to stop the spread of the Coronavirus, or COVID-19, have been stepped up in recent days Read more

Making a difference for people living with rare diseases
On 10 February 2020 (Parliament Magazine)

Innovative treatments and genetic testing can write a new chapter in the history of rare diseases, says Biogen's President,... Read more

About the EFPIA newsletter

The European Federation of Pharmaceutical Industries and Associations (EFPIA) represents the pharmaceutical industry operating in Europe. Through its direct membership of 37 national associations and 40 leading pharmaceutical companies, EFPIA is the voice on the EU scene of 1,900 companies committed to researching, developing and bringing to patients new medicines that will improve health and the quality of life around the world.

Tel: +32 (0)2 626 25 55
E-mail:Communications@efpia.eu